MeiraGTx Holdings plc 8-K

What Happened

• On April 16, 2026, MeiraGTx Holdings plc announced it entered into an underwriting agreement with BofA Securities and Goldman Sachs to sell 11,111,111 ordinary shares at $9.00 per share. The offering represents roughly $100.0 million in gross proceeds and is expected to close on April 17, 2026, subject to customary closing conditions. The company expects to receive approximately $93.3 million in net proceeds after underwriting discounts, commissions and estimated offering expenses.
• MeiraGTx said it will use the net proceeds for general corporate purposes, including working capital and capital expenditures, and believes the proceeds together with existing cash will fund operations — including potential commercial launches of bota-vec (for X‑linked retinitis pigmentosa) and AAV‑hAQP1 (for radiation‑induced xerostomia), if approved — into the second half of 2028. The underwriting agreement includes customary representations, indemnities and closing conditions. Counsel Walkers (Cayman) LLP issued an opinion on the validity of the ordinary shares.

Key Details

• Shares offered: 11,111,111 ordinary shares at $9.00 per share.
• Expected gross proceeds: approximately $100.0 million; expected net proceeds: approximately $93.3 million.
• Underwriters: BofA Securities, Inc. and Goldman Sachs & Co. LLC; expected closing date April 17, 2026 (subject to customary conditions).
• Planned use of proceeds: general corporate purposes, working capital, capital expenditures; company expects cash runway into H2 2028 to support potential product launches.

Why It Matters

• The offering provides MeiraGTx with fresh capital to support development and potential commercialization of key gene‑therapy candidates and to fund operations into 2028.
• New shares will dilute existing shareholders; investors should weigh the dilution against the benefit of an extended cash runway and the company’s stated plans to advance product candidates.
• The deal’s completion is subject to customary closing conditions and market factors; net proceeds and timing could change if the offering terms are altered or the offering does not close.